A Phase 3 clinical trial investigating wedge resection for ground-glass opacity-featured Lung Cancer reached its primary completion on 2025-11-30, having enrolled 286 participants.

Background

Lung cancer remains a leading cause of cancer-related mortality globally. Advances in imaging have led to increased detection of small, early-stage lung lesions, including those characterized by ground-glass opacity (GGO). These GGO-featured lesions often represent adenocarcinomas in situ, minimally invasive adenocarcinomas, or early invasive adenocarcinomas. The optimal surgical approach for these specific types of lesions, particularly those with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5, is an area of ongoing research. Wedge resection, a less invasive surgical procedure compared to lobectomy, aims to preserve lung function while effectively removing the cancerous tissue.

Trial design

This Phase 3 clinical trial, known as ECTOP-1020, enrolled 286 participants. The study focused on patients with Lung Cancer, specifically those with Ground-glass Opacity-featured lesions. The intervention under investigation was Wedge Resection. The trial's goal is to confirm the therapeutic effect of wedge resection for ground-glass opacity-featured lung cancer with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5.

What this means

The primary completion of this Phase 3 trial signifies that data collection for the primary endpoint has concluded for all enrolled participants. This milestone is a critical step towards understanding the efficacy and safety of wedge resection as a treatment option for specific ground-glass opacity-featured lung cancers. Once the collected data is analyzed and results are reported, clinicians and patients may gain further evidence to guide surgical decisions for this subset of early-stage lung cancer, potentially offering a less invasive yet effective treatment strategy.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for the study NCT06102161, titled "Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)", was recorded on 2025-11-30 on clinicaltrials.gov.